108 related articles for article (PubMed ID: 27485880)
1. Idelalisib-induced pneumonitis.
Gupta A; Li HC
BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27485880
[No Abstract] [Full Text] [Related]
2. Idelalisib-related pneumonitis.
Haustraete E; Obert J; Diab S; Abbes S; Zini JM; Valade S; Lerolle N; Albin N; Arnulf B; Bouaziz JD; Hussenet C; Tazi A; Bergeron A
Eur Respir J; 2016 Apr; 47(4):1280-3. PubMed ID: 26917607
[No Abstract] [Full Text] [Related]
3. Colitis due to idelalisib in a patient with follicular lymphoma.
Canelo-Vilaseca M; Ribera Santasusana JM; Sancho Cia JM
Med Clin (Barc); 2022 Jul; 159(2):106. PubMed ID: 35525678
[No Abstract] [Full Text] [Related]
4. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
Fukuhara N; Kinoshita T; Yamamoto K; Nagai H; Izutsu K; Yamamoto G; Bhargava P; Rajakumaraswamy N; Humeniuk R; Mathias A; Xing G; Fukui M; Tobinai K
Jpn J Clin Oncol; 2020 Dec; 50(12):1395-1402. PubMed ID: 32856068
[TBL] [Abstract][Full Text] [Related]
5. Abdominal Pain and Bloody Diarrhea.
Gupta A; Peng L; Li HC
JAMA Oncol; 2016 Oct; 2(10):1361-1362. PubMed ID: 27442133
[No Abstract] [Full Text] [Related]
6. Pulmonary adverse events related to idelalisib therapy: A single centre experience.
Migault C; Lebrun D; Toubas O; Nguyen Y; Giltat A; Julien G; Toubas D; Lebargy F; Delmer A; Bani-Sadr F
J Chemother; 2018 Sep; 30(5):318-322. PubMed ID: 30299215
[TBL] [Abstract][Full Text] [Related]
7. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.
Cuneo A; Barosi G; Danesi R; Fagiuoli S; Ghia P; Marzano A; Montillo M; Poletti V; Viale P; Zinzani PL
Hematol Oncol; 2019 Feb; 37(1):3-14. PubMed ID: 30187496
[TBL] [Abstract][Full Text] [Related]
8. Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides.
Louie CY; DiMaio MA; Matsukuma KE; Coutre SE; Berry GJ; Longacre TA
Am J Surg Pathol; 2015 Dec; 39(12):1653-60. PubMed ID: 26426383
[TBL] [Abstract][Full Text] [Related]
9. Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report.
Machan S; Plaza C; Pérez-González Y; Rodriguez-Pinilla M; Requena L; Cordoba R
J Med Case Rep; 2020 Feb; 14(1):35. PubMed ID: 32093776
[TBL] [Abstract][Full Text] [Related]
10. Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease.
Hammami MB; Al-Taee A; Meeks M; Fesler M; Hurley MY; Cao D; Lai JP
Clin J Gastroenterol; 2017 Apr; 10(2):142-146. PubMed ID: 28025783
[TBL] [Abstract][Full Text] [Related]
11. Discussion: Managing Risk When Using Idelalisib.
Coutre SE; Burger JA; Pagel JM
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):13. PubMed ID: 27168205
[No Abstract] [Full Text] [Related]
12. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.
Miller BW; Przepiorka D; de Claro RA; Lee K; Nie L; Simpson N; Gudi R; Saber H; Shord S; Bullock J; Marathe D; Mehrotra N; Hsieh LS; Ghosh D; Brown J; Kane RC; Justice R; Kaminskas E; Farrell AT; Pazdur R
Clin Cancer Res; 2015 Apr; 21(7):1525-9. PubMed ID: 25645861
[TBL] [Abstract][Full Text] [Related]
13. [Polymicrobial lung infection associated with idelalisib administration].
Rodríguez-Ferreras A; Velasco-Roces L; Lázaro-López E; Zapico-García I
Farm Hosp; 2018 Jan; 42(1):25-26. PubMed ID: 29306311
[No Abstract] [Full Text] [Related]
14. Multiple mucosal ulcerations caused by idelalisib.
Galeone M; Antiga E
Int J Dermatol; 2017 Sep; 56(9):e180-e181. PubMed ID: 28244069
[No Abstract] [Full Text] [Related]
15. Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity.
Castillo JJ; Gustine JN; Meid K; Dubeau T; Yang G; Xu L; Hunter ZR; Treon SP
Leuk Lymphoma; 2017 Apr; 58(4):1002-1004. PubMed ID: 27562445
[No Abstract] [Full Text] [Related]
16. Sequential disseminated aspergillosis and pulmonary tuberculosis in a patient treated by idelalisib for chronic lymphocytic leukemia.
Lafon-Desmurs B; Monsel G; Leblond V; Papo M; Caumes E; Fekkar A; Jaureguiberry S
Med Mal Infect; 2017 Jun; 47(4):293-296. PubMed ID: 27818019
[No Abstract] [Full Text] [Related]
17. Idelalisib: deaths from infections. Toxicity and doubtful efficacy.
Prescrire Int; 2016 Oct; 25(175):243. PubMed ID: 30688423
[No Abstract] [Full Text] [Related]
18. Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
Isidori A; Loscocco F; Visani G; Paolasini S; Scalzulli P; Musto P; Perrone T; Guarini A; Pastore D; Mazza P; Tonialini L; Pavone V; De Santis G; Tarantini G
Br J Haematol; 2022 Nov; 199(3):339-343. PubMed ID: 36002151
[TBL] [Abstract][Full Text] [Related]
19. Idelalisib approved for three blood cancers.
Traynor K
Am J Health Syst Pharm; 2014 Sep; 71(17):1430. PubMed ID: 25147161
[No Abstract] [Full Text] [Related]
20. Management of adverse events associated with idelalisib treatment: expert panel opinion.
Coutré SE; Barrientos JC; Brown JR; de Vos S; Furman RR; Keating MJ; Li D; O'Brien SM; Pagel JM; Poleski MH; Sharman JP; Yao NS; Zelenetz AD
Leuk Lymphoma; 2015; 56(10):2779-86. PubMed ID: 25726955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
